German commercial-stage diagnostic company CENTOGENE has formed a strategic collaboration with Lifera, a biopharmaceutical company owned by the Public Investment Fund. The collaboration aims to form a joint venture (JV) that will focus on providing multi-omic testing services in Saudi Arabia and the Gulf Cooperation Council countries.
As a part of the partnership agreement, CENTOGENE will receive a USD 30 million mandatory convertible loan from Lifera. The loan will have a six-month term and a conversion price of USD 2.20 per share of CENTOGENE's common stock. Additionally, CENTOGENE will also benefit from milestone payments and royalties related to the performance of the JV until 2033.
The partnership's objective is to improve local and regional access to advanced genetic testing by leveraging CENTOGENE's expertise and Lifera's local presence and resources. The JV will establish an advanced laboratory and bioinformatics infrastructure, utilizing CENTOGENE's biodata bank with over 70 million patient datasets, to offer state-of-the-art genetic sequencing tailored to regional needs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.